Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined wit… Read more
Puma Biotechnology Inc (PBYI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.111x
Based on the latest financial reports, Puma Biotechnology Inc (PBYI) has a cash flow conversion efficiency ratio of 0.111x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($14.42 Million) by net assets ($130.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Puma Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Puma Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Puma Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Puma Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kri-Kri Milk Industry S.A
AT:KRI
|
0.177x |
|
Wuxi Double Elephant Micro Fibre Material Co Ltd
SHE:002395
|
0.024x |
|
SGSG Science&technology Co Ltd Zhuhai
SHE:300561
|
0.008x |
|
PolEnergia S.A.
WAR:PEP
|
0.044x |
|
Zhuhai Winbase International Chemical Tank Terminal Co Ltd
SHE:002492
|
0.021x |
|
PT Ciputra Development Tbk
F:PUWA
|
0.033x |
|
Genesyslogic
TWO:6104
|
-0.012x |
|
Foshan Electrical and Lighting Co Ltd
SHE:200541
|
0.012x |
Annual Cash Flow Conversion Efficiency for Puma Biotechnology Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Puma Biotechnology Inc from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $130.34 Million | $41.80 Million | 0.321x | -24.08% |
| 2024-12-31 | $92.12 Million | $38.92 Million | 0.422x | -16.41% |
| 2023-12-31 | $53.44 Million | $27.01 Million | 0.505x | +169.00% |
| 2022-12-31 | $21.61 Million | $-15.83 Million | -0.732x | +91.32% |
| 2021-12-31 | $-2.45 Million | $20.65 Million | -8.442x | -6180.06% |
| 2020-12-31 | $-5.95 Million | $800.00K | -0.134x | -110.49% |
| 2019-12-31 | $17.46 Million | $22.38 Million | 1.281x | +282.40% |
| 2018-12-31 | $34.31 Million | $-24.10 Million | -0.703x | +78.29% |
| 2017-12-31 | $53.30 Million | $-172.50 Million | -3.236x | -379.22% |
| 2016-12-31 | $209.82 Million | $-141.70 Million | -0.675x | +9.95% |
| 2015-12-31 | $206.01 Million | $-154.50 Million | -0.750x | -13.71% |
| 2014-12-31 | $117.05 Million | $-77.20 Million | -0.660x | -0.63% |
| 2013-12-31 | $83.99 Million | $-55.05 Million | -0.655x | -92.03% |
| 2012-12-31 | $128.91 Million | $-44.00 Million | -0.341x | -916.91% |
| 2011-12-31 | $54.37 Million | $-1.83 Million | -0.034x | +99.97% |
| 2009-12-31 | $138.00 | $-16.82K | -121.848x | -2340.50% |
| 2008-12-31 | $-2.18K | $-11.83K | 5.438x | -- |
| 2007-12-31 | $0.00 | $-15.09 Million | x | -- |